Difference between revisions of "Part:BBa K5101006:Design"

(→‎Design Notes)
(→‎References)
 
(One intermediate revision by one other user not shown)
Line 11: Line 11:
 
===Source===
 
===Source===
  
−
The genes encoding these antibody fragments were synthesized based on sequences adapted for bacterial expression and optimized for E. coli, including an ompA signal sequence to direct the proteins to the periplasm. This localization is critical for proper protein folding and disulfide bond formation, essential for the functionality of the antibody. Certolizumab Pegol, used as the model for these fragments, is known for its efficacy in neutralizing TNF-α without Fc-mediated functions, which can be advantageous in reducing immunogenicity. For validation and scientific comparison, similar sequences used in this design are accessible in the NCBI database, which provides extensive data on various therapeutic antibodies.
+
The genes encoding these antibody fragments were synthesized based on sequences adapted for bacterial expression and optimized for <i>E. coli</i>, including an ompA signal sequence to direct the proteins to the periplasm. This localization is critical for proper protein folding and disulfide bond formation, essential for the functionality of the antibody. Certolizumab Pegol, used as the model for these fragments, is known for its efficacy in neutralizing TNF-&#945; without Fc-mediated functions, which can be advantageous in reducing immunogenicity. For validation and scientific comparison, similar sequences used in this design are accessible in the NCBI database, which provides extensive data on various therapeutic antibodies.
  
 
===References===
 
===References===
 +
1. Wang Xiangfeng, Li Yueyang, Guo Liangyu, et al. Research progress on certolizumab in the treatment of moderate to severe plaque psoriasis [J]. Practical Drugs and Clinical, 2019, 22(08): 886-890.
 +
 +
2. Chen Yating, Wang Qiaomin. Research progress on anti-tumor necrosis factor-α monoclonal antibodies for the treatment of Crohn's disease [J]. International Journal of Digestive Diseases, 2014, 34(04): 227-229+240.
 +
 +
3. Duan Zexing, Luo Junqing, Li Weiqiang. Study on the efficacy of infliximab combined with azathioprine in the treatment of moderate to severe Crohn's disease [J]. Gastroenterology, 2013, 18: 229-232.
 +
 +
4. Talaei A, Mazaheri S, Bayat E, et al. Production of Soluble and Functional Anti-TNF-α Fab' Fragment in Cytoplasm of E. coli: Investigating the Effect of Process Conditions on Cellular Biomass and Protein Yield Using Response Surface Methodology[J]. The Protein Journal. 2021, 40(5): 786-798.

Latest revision as of 19:51, 1 October 2024


Certolizumab (Anti-TNF-α )Light Chain With OmpA


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


Design Notes

The genes encoding these antibody fragments were synthesized based on sequences adapted for bacterial expression and optimized for E. coli, including an ompA signal sequence to direct the proteins to the periplasm. This localization is critical for proper protein folding and disulfide bond formation, essential for the functionality of the antibody. Certolizumab Pegol, used as the model for these fragments, is known for its efficacy in neutralizing TNF-α without Fc-mediated functions, which can be advantageous in reducing immunogenicity. For validation and scientific comparison, similar sequences used in this design are accessible in the NCBI database, which provides extensive data on various therapeutic antibodies.

Source

The genes encoding these antibody fragments were synthesized based on sequences adapted for bacterial expression and optimized for E. coli, including an ompA signal sequence to direct the proteins to the periplasm. This localization is critical for proper protein folding and disulfide bond formation, essential for the functionality of the antibody. Certolizumab Pegol, used as the model for these fragments, is known for its efficacy in neutralizing TNF-α without Fc-mediated functions, which can be advantageous in reducing immunogenicity. For validation and scientific comparison, similar sequences used in this design are accessible in the NCBI database, which provides extensive data on various therapeutic antibodies.

References

1. Wang Xiangfeng, Li Yueyang, Guo Liangyu, et al. Research progress on certolizumab in the treatment of moderate to severe plaque psoriasis [J]. Practical Drugs and Clinical, 2019, 22(08): 886-890.

2. Chen Yating, Wang Qiaomin. Research progress on anti-tumor necrosis factor-α monoclonal antibodies for the treatment of Crohn's disease [J]. International Journal of Digestive Diseases, 2014, 34(04): 227-229+240.

3. Duan Zexing, Luo Junqing, Li Weiqiang. Study on the efficacy of infliximab combined with azathioprine in the treatment of moderate to severe Crohn's disease [J]. Gastroenterology, 2013, 18: 229-232.

4. Talaei A, Mazaheri S, Bayat E, et al. Production of Soluble and Functional Anti-TNF-α Fab' Fragment in Cytoplasm of E. coli: Investigating the Effect of Process Conditions on Cellular Biomass and Protein Yield Using Response Surface Methodology[J]. The Protein Journal. 2021, 40(5): 786-798.